ACRO Biomedical Co., Ltd. (TPEX:6748)
Taiwan · Delayed Price · Currency is TWD 65.30
-6.90 (-9.56%)
Oct 9, 2025, 2:59 PM CST
ACRO Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| 36.5 | 44.23 | 51.06 | 27.63 | 21.83 | 18.03 | Upgrade | |
Revenue Growth (YoY) | -35.17% | -13.38% | 84.79% | 26.59% | 21.04% | 146.35% | Upgrade |
Cost of Revenue | 18.96 | 18.04 | 11.95 | 14.21 | 7.29 | 9.46 | Upgrade |
Gross Profit | 17.54 | 26.19 | 39.12 | 13.43 | 14.54 | 8.58 | Upgrade |
Selling, General & Admin | 71.6 | 66.97 | 55.59 | 48.36 | 42.05 | 32.84 | Upgrade |
Research & Development | 28.23 | 25.72 | 28.64 | 27.85 | 26.04 | 31.7 | Upgrade |
Operating Expenses | 97.97 | 90.84 | 87.79 | 76.2 | 68.1 | 64.54 | Upgrade |
Operating Income | -80.43 | -64.65 | -48.67 | -62.78 | -53.55 | -55.97 | Upgrade |
Interest Expense | -0.26 | -0.29 | -0.26 | -0.1 | -0.09 | -0.1 | Upgrade |
Interest & Investment Income | 5.69 | 4.35 | 2.33 | 0.8 | 0.32 | 0.21 | Upgrade |
Currency Exchange Gain (Loss) | 0.09 | -0.19 | -0.24 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 0.63 | 0.19 | 2.65 | 1.2 | 2.55 | 5.84 | Upgrade |
EBT Excluding Unusual Items | -74.28 | -60.59 | -44.19 | -60.88 | -50.78 | -50.02 | Upgrade |
Gain (Loss) on Sale of Investments | -5.38 | -1.33 | 2.77 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -0.17 | -0.15 | - | - | - | - | Upgrade |
Pretax Income | -79.82 | -62.07 | -41.42 | -60.88 | -50.78 | -50.02 | Upgrade |
Income Tax Expense | - | 0.02 | - | - | - | - | Upgrade |
Net Income | -79.82 | -62.09 | -41.42 | -60.88 | -50.78 | -50.02 | Upgrade |
Net Income to Common | -79.82 | -62.09 | -41.42 | -60.88 | -50.78 | -50.02 | Upgrade |
Shares Outstanding (Basic) | 61 | 61 | 53 | 47 | 36 | 30 | Upgrade |
Shares Outstanding (Diluted) | 61 | 61 | 53 | 47 | 36 | 30 | Upgrade |
Shares Change (YoY) | 6.10% | 16.17% | 11.65% | 32.92% | 17.13% | 20.39% | Upgrade |
EPS (Basic) | -1.30 | -1.01 | -0.79 | -1.29 | -1.43 | -1.65 | Upgrade |
EPS (Diluted) | -1.30 | -1.01 | -0.79 | -1.29 | -1.43 | -1.65 | Upgrade |
Free Cash Flow | -69.3 | -73.93 | -69.27 | -49.45 | -48.2 | -33.45 | Upgrade |
Free Cash Flow Per Share | -1.13 | -1.21 | -1.31 | -1.05 | -1.36 | -1.10 | Upgrade |
Gross Margin | 48.06% | 59.21% | 76.60% | 48.59% | 66.62% | 47.55% | Upgrade |
Operating Margin | -220.35% | -146.17% | -95.31% | -227.17% | -245.34% | -310.35% | Upgrade |
Profit Margin | -218.69% | -140.37% | -81.11% | -220.33% | -232.61% | -277.37% | Upgrade |
Free Cash Flow Margin | -189.85% | -167.13% | -135.66% | -178.94% | -220.80% | -185.50% | Upgrade |
EBITDA | -71.02 | -58.18 | -43.75 | -53.56 | -44.05 | -43.43 | Upgrade |
EBITDA Margin | -194.58% | -131.54% | -85.69% | -193.84% | -201.80% | -240.84% | Upgrade |
D&A For EBITDA | 9.41 | 6.47 | 4.92 | 9.21 | 9.51 | 12.54 | Upgrade |
EBIT | -80.43 | -64.65 | -48.67 | -62.78 | -53.55 | -55.97 | Upgrade |
EBIT Margin | -220.35% | -146.17% | -95.31% | -227.17% | -245.34% | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.